SBTX vs. AKRO, GERN, BLTE, IRON, AMPH, WVE, MNKD, DVAX, INDV, and GLPG
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Akero Therapeutics (AKRO), Geron (GERN), Belite Bio (BLTE), Disc Medicine (IRON), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), MannKind (MNKD), Dynavax Technologies (DVAX), Indivior (INDV), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics vs.
Silverback Therapeutics (NASDAQ:SBTX) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
Akero Therapeutics received 91 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 63.74% of users gave Akero Therapeutics an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
In the previous week, Akero Therapeutics had 8 more articles in the media than Silverback Therapeutics. MarketBeat recorded 9 mentions for Akero Therapeutics and 1 mentions for Silverback Therapeutics. Akero Therapeutics' average media sentiment score of 0.25 beat Silverback Therapeutics' score of 0.00 indicating that Akero Therapeutics is being referred to more favorably in the news media.
Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.
Akero Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Silverback Therapeutics' return on equity of -29.62% beat Akero Therapeutics' return on equity.
Akero Therapeutics has a consensus target price of $46.83, indicating a potential upside of 86.41%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Silverback Therapeutics.
74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Silverback Therapeutics beats Akero Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SBTX) was last updated on 1/22/2025 by MarketBeat.com Staff
